These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24943810)

  • 61. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.
    Wang L; Qian J; Lu Y; Li H; Bao H; He D; Liu Z; Zheng Y; He J; Li Y; Neelapu S; Yang J; Kwak LW; Yi Q; Cai Z
    Haematologica; 2013 Sep; 98(9):1458-66. PubMed ID: 23508008
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
    Ray A; Das DS; Song Y; Hideshima T; Tai YT; Chauhan D; Anderson KC
    Leukemia; 2018 Mar; 32(3):843-846. PubMed ID: 29104288
    [No Abstract]   [Full Text] [Related]  

  • 63. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
    Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
    Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Apr; 11(6):457-460. PubMed ID: 30860440
    [No Abstract]   [Full Text] [Related]  

  • 65. Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial.
    Gurizzan C; Lorini L; Paderno A; Tomasoni M; Zigliani G; Bozzola A; Ardighieri L; Battocchio S; Bignotti E; Ravaggi A; Romani C; De Cecco L; Serafini MS; Miceli R; Bardellini E; Majorana A; Piazza C; Bossi P
    BMC Cancer; 2021 May; 21(1):561. PubMed ID: 34001010
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role.
    Eisen T
    Eur J Cancer; 2015 Nov; 51(17):2578-9. PubMed ID: 26613659
    [No Abstract]   [Full Text] [Related]  

  • 67. Novel Immunologic Approaches to Melanoma Treatment.
    Escandell I; Martín JM; Jordá E
    Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination Strategies PD-1/PD-L1 Antagonists.
    Sznol M
    Cancer J; 2018; 24(1):54-57. PubMed ID: 29360729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
    Lin RJ; Diefenbach CS
    Oncology (Williston Park); 2016 Oct; 30(10):914-20. PubMed ID: 27753058
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.
    Ma Q; Long W; Xing C; Chu J; Luo M; Wang HY; Liu Q; Wang RF
    Front Immunol; 2018; 9():2924. PubMed ID: 30619286
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Pérez-Segura P
    Anticancer Drugs; 2019 Feb; 30(2):149-152. PubMed ID: 30339560
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Stem cells--targets for antitumor therapy].
    Shvartsburd PM
    Vopr Onkol; 2011; 57(1):7-13. PubMed ID: 21598702
    [No Abstract]   [Full Text] [Related]  

  • 74. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
    Gravis G; Billon E; Baldini C; Massard C; Hilgers W; Delva R; Walz J; Pignot G; Rybikowski S; Dermeche S; Thomassin J; Brunelle S; Lavaud P; Loriot Y;
    Eur J Cancer; 2018 Nov; 104():236-238. PubMed ID: 30316610
    [No Abstract]   [Full Text] [Related]  

  • 76. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
    Zhou L; Xu Q; Huang L; Jin J; Zuo X; Zhang Q; Ye L; Zhu S; Zhan P; Ren J; Lv T; Song Y
    Cancer Lett; 2021 Mar; 500():163-171. PubMed ID: 33278498
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.
    Ahmad SM; Larsen SK; Svane IM; Andersen MH
    Leukemia; 2014 Jan; 28(1):236-8. PubMed ID: 24091833
    [No Abstract]   [Full Text] [Related]  

  • 79. Immunotherapy of Colon Cancer.
    Stein A; Folprecht G
    Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
    Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
    Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.